CN101151264B - 喹啉酮甲酰胺化合物的结晶形式 - Google Patents

喹啉酮甲酰胺化合物的结晶形式 Download PDF

Info

Publication number
CN101151264B
CN101151264B CN2006800107676A CN200680010767A CN101151264B CN 101151264 B CN101151264 B CN 101151264B CN 2006800107676 A CN2006800107676 A CN 2006800107676A CN 200680010767 A CN200680010767 A CN 200680010767A CN 101151264 B CN101151264 B CN 101151264B
Authority
CN
China
Prior art keywords
crystalline
oxo
dihydroquinoline
amino
isopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN2006800107676A
Other languages
English (en)
Chinese (zh)
Other versions
CN101151264A (zh
Inventor
保罗·R·法瑟雷
S·德里克·特纳
亚当·戈德布卢姆
罗伯特·晁
丹尼尔·格诺夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpha Sigma
Original Assignee
Shiwan Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiwan Pharmaceutical filed Critical Shiwan Pharmaceutical
Publication of CN101151264A publication Critical patent/CN101151264A/zh
Application granted granted Critical
Publication of CN101151264B publication Critical patent/CN101151264B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2006800107676A 2005-04-06 2006-04-05 喹啉酮甲酰胺化合物的结晶形式 Expired - Lifetime CN101151264B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66878005P 2005-04-06 2005-04-06
US60/668,780 2005-04-06
PCT/US2006/012978 WO2006108127A2 (en) 2005-04-06 2006-04-05 Crystalline form of a quinolinone-carboxamide compound

Publications (2)

Publication Number Publication Date
CN101151264A CN101151264A (zh) 2008-03-26
CN101151264B true CN101151264B (zh) 2011-07-06

Family

ID=37074104

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800107676A Expired - Lifetime CN101151264B (zh) 2005-04-06 2006-04-05 喹啉酮甲酰胺化合物的结晶形式

Country Status (29)

Country Link
US (4) US7728004B2 (https=)
EP (1) EP1874766B1 (https=)
JP (2) JP5230407B2 (https=)
KR (1) KR101322873B1 (https=)
CN (1) CN101151264B (https=)
AR (2) AR053208A1 (https=)
AT (1) ATE479682T1 (https=)
AU (1) AU2006232129B2 (https=)
BR (1) BRPI0610657A2 (https=)
CA (1) CA2603654C (https=)
CY (1) CY1111275T1 (https=)
DE (1) DE602006016586D1 (https=)
DK (1) DK1874766T3 (https=)
EA (1) EA012115B1 (https=)
ES (1) ES2350495T3 (https=)
HR (1) HRP20100629T1 (https=)
IL (1) IL186023A (https=)
MA (1) MA29403B1 (https=)
MX (1) MX2007012438A (https=)
MY (1) MY151075A (https=)
NO (1) NO339699B1 (https=)
NZ (1) NZ561900A (https=)
PE (1) PE20061310A1 (https=)
PL (1) PL1874766T3 (https=)
PT (1) PT1874766E (https=)
SI (1) SI1874766T1 (https=)
TW (1) TWI377206B (https=)
WO (1) WO2006108127A2 (https=)
ZA (1) ZA200708071B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063671B2 (en) * 2002-06-21 2006-06-20 Boston Scientific Scimed, Inc. Electronically activated capture device
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US7399862B2 (en) * 2004-11-05 2008-07-15 Theravance, Inc. 5-HT4 receptor agonist compounds
WO2006052889A2 (en) 2004-11-05 2006-05-18 Theravance, Inc. Quinolinone-carboxamide compounds
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
CN102775396B (zh) 2005-11-08 2014-10-08 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的杂环调控剂
EP2160188A2 (en) * 2007-05-17 2010-03-10 Theravance, Inc. Prokinetic agent for bowel preparation
CH698729B1 (de) * 2007-05-30 2009-10-15 Cerbios Pharma Sa Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure.
EP3683218B1 (en) 2007-12-07 2024-09-18 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
SMT201800036T1 (it) * 2009-04-13 2018-03-08 Theravance Biopharma R&D Ip Llc Combinazioni di agonisti di recettore 5-ht4 e inibitori di acetilcolinesterasi per il trattamento di disturbi cognitivi
WO2011092290A1 (en) 2010-02-01 2011-08-04 Novartis Ag Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
JP2013523833A (ja) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
AU2014349010C1 (en) 2013-11-12 2020-08-06 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
KR102692887B1 (ko) * 2017-07-31 2024-08-08 알파시그마 에스.피.에이. 벨루세트라그를 사용하여 위마비 증상을 치료하는 방법
US10570127B1 (en) 2018-11-05 2020-02-25 Renexxion, Llc Material and methods for the treatment of gastro-intestinal disorders
CA3263063A1 (en) 2022-09-20 2024-03-28 Alfasigma S.P.A. VELUSETRAG INTENDED FOR USE IN THE TREATMENT OF CHRONIC INTESTINAL PSEUDO-OBSTRUCTION (CIPO)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564650B1 (en) * 1990-12-28 1995-09-20 Kyowa Hakko Kogyo Co., Ltd. Quinoline derivative
WO2005100350A1 (en) * 2004-04-07 2005-10-27 Theravance, Inc. Quinolinone-carboxamide compounds as 5-ht4 receptor agonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3122671B2 (ja) 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
WO1994012497A1 (fr) 1992-11-20 1994-06-09 Taisho Pharmaceutical Co., Ltd. Compose heterocyclique
JP3829879B2 (ja) 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
TW548103B (en) * 1997-07-11 2003-08-21 Janssen Pharmaceutica Nv Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
US7105195B2 (en) * 2003-07-25 2006-09-12 General Mills, Inc. Reduced trans fat product
BRPI0416813A (pt) 2003-11-24 2007-03-06 Pfizer compostos de ácido quinolonacarboxìlico com atividade agonista do receptor 5-ht4
US7728006B2 (en) 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
WO2006052889A2 (en) 2004-11-05 2006-05-18 Theravance, Inc. Quinolinone-carboxamide compounds
US7399862B2 (en) 2004-11-05 2008-07-15 Theravance, Inc. 5-HT4 receptor agonist compounds
WO2006088988A1 (en) 2005-02-17 2006-08-24 Theravance, Inc. Crystalline form of an indazole-carboxamide compound
CN101163701A (zh) 2005-03-02 2008-04-16 施万制药 作为5-ht4受体激动剂的喹啉酮化合物
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564650B1 (en) * 1990-12-28 1995-09-20 Kyowa Hakko Kogyo Co., Ltd. Quinoline derivative
WO2005100350A1 (en) * 2004-04-07 2005-10-27 Theravance, Inc. Quinolinone-carboxamide compounds as 5-ht4 receptor agonists

Also Published As

Publication number Publication date
PL1874766T3 (pl) 2011-02-28
AU2006232129A1 (en) 2006-10-12
MA29403B1 (fr) 2008-04-01
JP5230407B2 (ja) 2013-07-10
CN101151264A (zh) 2008-03-26
WO2006108127A3 (en) 2007-01-04
EA012115B1 (ru) 2009-08-28
IL186023A0 (en) 2008-01-20
EA200702161A1 (ru) 2008-04-28
US20060229332A1 (en) 2006-10-12
WO2006108127A2 (en) 2006-10-12
NO20075574L (no) 2007-11-02
JP2008535848A (ja) 2008-09-04
ZA200708071B (en) 2008-10-29
CA2603654C (en) 2014-05-27
SI1874766T1 (sl) 2010-12-31
AU2006232129B2 (en) 2012-07-12
CA2603654A1 (en) 2006-10-12
MX2007012438A (es) 2007-12-05
AR110019A2 (es) 2019-02-13
HRP20100629T1 (hr) 2010-12-31
CY1111275T1 (el) 2015-08-05
NO339699B1 (no) 2017-01-23
US7728004B2 (en) 2010-06-01
US20160095849A1 (en) 2016-04-07
PE20061310A1 (es) 2007-01-23
IL186023A (en) 2011-09-27
TW200643020A (en) 2006-12-16
ATE479682T1 (de) 2010-09-15
DE602006016586D1 (de) 2010-10-14
NZ561900A (en) 2010-12-24
ES2350495T3 (es) 2011-01-24
DK1874766T3 (da) 2010-12-06
EP1874766B1 (en) 2010-09-01
US20140256769A1 (en) 2014-09-11
US8658671B2 (en) 2014-02-25
US9402840B2 (en) 2016-08-02
PT1874766E (pt) 2010-11-30
MY151075A (en) 2014-03-31
KR20070116988A (ko) 2007-12-11
JP2012153725A (ja) 2012-08-16
US20100197728A1 (en) 2010-08-05
US9126994B2 (en) 2015-09-08
EP1874766A2 (en) 2008-01-09
KR101322873B1 (ko) 2013-10-30
TWI377206B (en) 2012-11-21
AR053208A1 (es) 2007-04-25
BRPI0610657A2 (pt) 2010-07-13
HK1110866A1 (en) 2008-07-25

Similar Documents

Publication Publication Date Title
US9402840B2 (en) Crystalline form of a quinolinone-carboxamide compound
US9873692B2 (en) Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
EP1807423B1 (en) Quinolinone-carboxamide compounds
US8288550B2 (en) Crystalline form of a benzimidazole-carboxamide medicinal compound
US20060183901A1 (en) Crystalline form of an indazole-carboxamide compound
US7728006B2 (en) Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US20100285519A1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
HK1110866B (en) Crystalline form of a quinolinone-carboxamide compound

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: SCHWAN BIOPHARMA RESEARCH + DEVELOPMENT IP CO., LT

Free format text: FORMER OWNER: SCHWAN PHARMACY

Effective date: 20140901

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20140901

Address after: California, USA

Patentee after: THERAVANCE BIOPHARMA R&D IP, LLC

Address before: California, USA

Patentee before: Shi Wanzhiyao

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20250304

Address after: Bologna, Italy

Patentee after: Alpha Sigma

Country or region after: Italy

Address before: California, USA

Patentee before: THERAVANCE BIOPHARMA R&D IP, LLC

Country or region before: U.S.A.

CX01 Expiry of patent term

Granted publication date: 20110706